Personalis Inc (PSNL)

$1.21

+0.01

(+0.83%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Personalis Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 16.69M → 19.67M (in $), with an average increase of 7.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -29.09M → -26.58M (in $), with an average increase of 9.5% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 67.2%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 100.0%

Performance

  • $1.18
    $1.27
    $1.21
    downward going graph

    2.48%

    Downside

    Day's Volatility :7.09%

    Upside

    4.72%

    downward going graph
  • $0.89
    $2.74
    $1.21
    downward going graph

    26.4%

    Downside

    52 Weeks Volatility :67.5%

    Upside

    55.84%

    downward going graph

Returns

PeriodPersonalis IncSector (Health Care)Index (Russel 2000)
3 Months
-25.93%
-0.7%
0.0%
6 Months
11.63%
6.6%
0.0%
1 Year
-55.06%
3.7%
-1.5%
3 Years
-94.4%
14.0%
-21.8%

Highlights

Market Capitalization
63.5M
Book Value
$2.56
Earnings Per Share (EPS)
-2.25
Wall Street Target Price
4.75
Profit Margin
-147.38%
Operating Margin TTM
-101.31%
Return On Assets TTM
-23.25%
Return On Equity TTM
-62.31%
Revenue TTM
73.5M
Revenue Per Share TTM
1.53
Quarterly Revenue Growth YOY
17.7%
Gross Profit TTM
13.4M
EBITDA
-85.0M
Diluted Eps TTM
-2.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.58
EPS Estimate Next Year
-1.35
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Personalis Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 292.56%

Current $1.21
Target $4.75

Company Financials

FY18Y/Y Change
Revenue
37.8M
↑ 302.15%
Net Income
-19.9M
↓ 15.73%
Net Profit Margin
-52.64%
↑ 198.59%
FY19Y/Y Change
Revenue
65.2M
↑ 72.62%
Net Income
-25.1M
↑ 26.14%
Net Profit Margin
-38.47%
↑ 14.17%
FY20Y/Y Change
Revenue
78.6M
↑ 20.61%
Net Income
-41.3M
↑ 64.57%
Net Profit Margin
-52.49%
↓ 14.02%
FY21Y/Y Change
Revenue
85.5M
↑ 8.7%
Net Income
-65.2M
↑ 58.01%
Net Profit Margin
-76.29%
↓ 23.8%
FY22Y/Y Change
Revenue
65.0M
↓ 23.92%
Net Income
-113.3M
↑ 73.73%
Net Profit Margin
-174.2%
↓ 97.91%
FY23Y/Y Change
Revenue
73.5M
↑ 12.97%
Net Income
-108.3M
↓ 4.43%
Net Profit Margin
-147.38%
↑ 26.82%
Q3 FY22Q/Q Change
Revenue
14.9M
↓ 18.54%
Net Income
-26.5M
↓ 3.83%
Net Profit Margin
-178.3%
↓ 27.28%
Q4 FY22Q/Q Change
Revenue
16.7M
↑ 12.55%
Net Income
-31.1M
↑ 17.27%
Net Profit Margin
-185.79%
↓ 7.49%
Q1 FY23Q/Q Change
Revenue
18.9M
↑ 12.79%
Net Income
-28.7M
↓ 7.75%
Net Profit Margin
-151.96%
↑ 33.83%
Q2 FY23Q/Q Change
Revenue
16.7M
↓ 11.46%
Net Income
-24.0M
↓ 16.41%
Net Profit Margin
-143.45%
↑ 8.51%
Q3 FY23Q/Q Change
Revenue
18.2M
↑ 9.27%
Net Income
-29.1M
↑ 21.47%
Net Profit Margin
-159.47%
↓ 16.02%
Q4 FY23Q/Q Change
Revenue
19.7M
↑ 7.83%
Net Income
-26.6M
↓ 8.64%
Net Profit Margin
-135.12%
↑ 24.35%
FY18Y/Y Change
Total Assets
41.7M
↑ 24.15%
Total Liabilities
148.1M
↑ 17.35%
FY19Y/Y Change
Total Assets
157.3M
↑ 277.47%
Total Liabilities
50.6M
↓ 65.82%
FY20Y/Y Change
Total Assets
244.8M
↑ 55.66%
Total Liabilities
49.9M
↓ 1.39%
FY21Y/Y Change
Total Assets
396.5M
↑ 61.95%
Total Liabilities
86.2M
↑ 72.81%
FY22Y/Y Change
Total Assets
292.7M
↓ 26.18%
Total Liabilities
74.6M
↓ 13.53%
FY23Y/Y Change
Total Assets
225.1M
↓ 23.1%
Total Liabilities
95.7M
↑ 28.29%
Q3 FY22Q/Q Change
Total Assets
317.9M
↓ 11.21%
Total Liabilities
75.5M
↓ 19.16%
Q4 FY22Q/Q Change
Total Assets
292.7M
↓ 7.92%
Total Liabilities
74.6M
↓ 1.19%
Q1 FY23Q/Q Change
Total Assets
272.2M
↓ 7.01%
Total Liabilities
78.5M
↑ 5.35%
Q2 FY23Q/Q Change
Total Assets
249.0M
↓ 8.5%
Total Liabilities
73.0M
↓ 7.12%
Q3 FY23Q/Q Change
Total Assets
226.6M
↓ 9.0%
Total Liabilities
75.4M
↑ 3.4%
Q4 FY23Q/Q Change
Total Assets
225.1M
↓ 0.68%
Total Liabilities
95.7M
↑ 26.82%
FY18Y/Y Change
Operating Cash Flow
5.6M
↑ 1821.38%
Investing Cash Flow
-7.9M
↑ 52.23%
Financing Cash Flow
-591.0K
↓ 103.6%
FY19Y/Y Change
Operating Cash Flow
-18.1M
↓ 424.28%
Investing Cash Flow
-81.6M
↑ 938.96%
Financing Cash Flow
134.9M
↓ 22933.84%
FY20Y/Y Change
Operating Cash Flow
-42.7M
↑ 136.06%
Investing Cash Flow
-65.1M
↓ 20.15%
Financing Cash Flow
121.3M
↓ 10.14%
FY21Y/Y Change
Operating Cash Flow
-70.8M
↑ 66.06%
Investing Cash Flow
-60.1M
↓ 7.79%
Financing Cash Flow
169.7M
↑ 39.94%
FY22Y/Y Change
Operating Cash Flow
-70.2M
↓ 0.84%
Investing Cash Flow
52.5M
↓ 187.46%
Financing Cash Flow
1.4M
↓ 99.2%
Q3 FY22Q/Q Change
Operating Cash Flow
-14.8M
↓ 46.01%
Investing Cash Flow
10.8M
↓ 52.97%
Financing Cash Flow
760.0K
↓ 280.95%
Q4 FY22Q/Q Change
Operating Cash Flow
-16.8M
↑ 13.53%
Investing Cash Flow
21.9M
↑ 101.84%
Financing Cash Flow
511.0K
↓ 32.76%
Q1 FY23Q/Q Change
Operating Cash Flow
-15.7M
↓ 6.07%
Investing Cash Flow
13.8M
↓ 36.88%
Financing Cash Flow
925.0K
↑ 81.02%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.4M
↓ 33.86%
Investing Cash Flow
19.5M
↑ 41.73%
Financing Cash Flow
925.0K
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-16.7M
↑ 60.18%
Investing Cash Flow
-8.6M
↓ 144.02%
Financing Cash Flow
290.0K
↓ 68.65%

Technicals Summary

Sell

Neutral

Buy

Personalis Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Personalis Inc
Personalis Inc
-26.38%
11.63%
-55.06%
-94.4%
-95.79%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Personalis Inc
Personalis Inc
NA
NA
NA
-1.58
-0.62
-0.23
NA
2.56
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Personalis Inc
Personalis Inc
Buy
$63.5M
-95.79%
NA
-147.38%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • ARK Investment Management LLC

    13.21%

  • BlackRock Inc

    6.56%

  • Vanguard Group Inc

    4.10%

  • Alyeska Investment Group, L.P.

    2.47%

  • Sumitomo Mitsui Trust Holdings Inc

    2.15%

  • Nikko Asset Management Americas Inc

    2.15%

Corporate Announcements

  • Personalis Inc Earnings

    Personalis Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Organization
Personalis Inc
Employees
223
CEO
Mr. Christopher M. Hall
Industry
Biotechnology

Discover More

FAQs